AstraZeneca hit by patent expiries as sales slump
Drugmaker AstraZeneca has showed it is still languishing in intensive care after patent expiries triggered an 8 per per cent fall in sales to $25.7
Despite new chief executive Pascal Soriot’s recent string of acquisitions to boost Astra’s pipeline, the pharmaceuticals giant admitted that it expects revenues to fall again this year by “a low-to-mid-single-digit percentage”.
Astra is suffering from blockbuster drugs, including cholesterol-buster Crestor and heartburn and ulcer treatment Nexium, facing cheaper, generic competition in Australia and Europe respectively.
Those patent expiries, as well as the cost of acquisitions, including spending up to $4.1 billion buying out rival Bristol-Myers Squibb’s stake in a diabetes-medicine development venture, saw Astra’s pre-tax profit crash 57 per cent to $3.3 billion in 2013.
In the crucial United States market, Astra’s revenues fell 7 per cent in the last three months of 2013, while in Europe, where treatments including anti-psychotic drug Seroquel IR dropped out of patent, sales lost 2 per cent in the same period.
The US picture is set to worsen this year: from May, Nexium will face generic competition. Astra admitted that US healthcare reforms, which force drugmakers to pay annual fees, had cost $318 million in the fourth quarter.
Soriot, who has cut Astra’s headcount by more than 11,000 over two years, said: “Our financial performance for 2013 reflects the ongoing impact from the loss of exclusivity for several key brands. In the near term these headwinds will remain challenging, however I am confident that we can return to growth… and expect our 2017 revenues will be broadly in line with 2013.”
He also said Astra’s late-stage pipeline of drugs that are close to being put forward for regulatory approval has nearly doubled.
The shares fell 3.5%, or 135.5p, to 3741.5p.
- 1 Autistic adults could take pure MDMA to 'reduce social anxiety'
- 2 Stolen Instagram photo sells for $90,000
- 3 Before you complain about your GP, this is what you need to know about actually doing the job
- 4 Charlie Charlie Challenge explained: not a Mexican demon being summoned — it's gravity
- 5 Paracetamol Challenge: Mother of girl killed by overdose pleads with teenagers not to take part
Iran launches anti-Isis cartoon competition 'to expose true nature of Islamic State'
'Don't blame all men for rape' campaign backfires spectacularly
Fifa corruption arrests: How Chuck Blazer rinsed money from the beautiful game
Fifa corruption live: Uefa to consider pulling teams from Fifa tournaments if Blatter stays
Ukip MP Douglas Carswell says he felt his safety was 'seriously at risk' after he was surrounded by anti-austerity protesters
EU referendum: David Cameron's rules are a 'democratic disgrace', says French-born Scottish politician set to be denied a vote
The day that Britain resigned as a global power
SNP fury as HS2 finds 'no business case' for taking fast train service to Scotland
Australian man punched in the face for defending Muslim women from abuse on train
A nation of inequality: How the UK is failing to feed its most vulnerable people
David Starkey 'tells Amal Clooney to shut up and stop over-promoting human rights'
iJobs Money & Business
£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...
£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...
£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...